8-K 1 d8k.htm FORM 8-K FORM 8-K

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): April 24, 2003

 

 

CuraGen Corporation

(Exact name of registrant as specified in its charter)

 

Delaware

     

0-23223

     

06-1331400

     
    

(State or other

jurisdiction of

incorporation)

     

(Commission

File Number)

     

(IRS Employer

Identification No.)

 

555 Long Wharf Drive, 11th Floor

New Haven, Connecticut 06511

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (203) 401-3330

 

 

 

Item 7.    Financial Statements and Exhibits.

 

(c) The following exhibits are filed with this report:

 

Exhibit Number

   

Description

99.1

   

Press Release dated April 24, 2003.

 

Item 9.    Regulation FD Disclosure.

 

The following information is provided pursuant to Item 12, “Disclosure of Results of Operations and Financial Condition.”

 

On April 24, 2003, the Registrant issued a press release to report its financial results for the quarter ended March 31, 2003. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

 

In accordance with the procedural guidance in SEC Release No. 33-8216, the information in this Form 8-K and the Exhibit attached to this Form 8-K are being furnished under “Item 9. Regulation FD Disclosure” rather than under “Item 12. Disclosure of Results of Operations and Financial Condition.” The information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CURAGEN CORPORATION

(Registrant)

 

 

 

Date: April 24, 2003

By:     /s/ David M. Wurzer                    

Name:    David M. Wurzer

Title:      Executive Vice President and

                Chief Financial Officer